Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
NCT ID: NCT00560235
Last Updated: 2015-10-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
138 participants
INTERVENTIONAL
2008-03-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
NCT05755113
A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)
NCT00617890
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
NCT00720174
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
NCT04996004
CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT00017446
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CP-751,871
Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-751,871
Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current disease state for which there is no curative therapy
Exclusion Criteria
* Concurrent treatment with other anti-cancer agents
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Rochester, Minnesota, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Providence, Rhode Island, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Brisbane, Queensland, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Providencia, Santiago, RM, Chile
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Villejuif, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Jerusalem, , Israel
Pfizer Investigational Site
Petah Tikva, , Israel
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Torino, , Italy
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Esplugues de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Sutton, Surrey, United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Oxford, , United Kingdom
Pfizer Investigational Site
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A4021020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.